News >

Langer Highlights the Impact of Chemoimmunotherapy in NSCLC

Angelica Welch
Published: Tuesday, Jul 24, 2018

Corey J. Langer, MD

Corey J. Langer, MD

There has been a major paradigm shift with the combination of immunotherapy and chemotherapy in non–small cell lung cancer (NSCLC), according to Corey J. Langer, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication